X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Pivya (pivmecillinam) oral tablets have been approved by the FDA for treating uncomplicated urinary tract infections (UTIs) in adult females caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
Lead Product(s): Pivmecillinam
Therapeutic Area: Infections and Infectious Diseases Product Name: Pivya
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2024
Details:
The net proceeds will be used for the development and commercialization of two European-approved antibiotics, including Pivya (pivmecillinam), an oral prodrug of mecillinam, and mecillinam, an intravenous (IV) formulation, for the treatment of urinary tract infections.
Lead Product(s): Pivmecillinam
Therapeutic Area: Infections and Infectious Diseases Product Name: Pivya
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AMR Action Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 17, 2024
Details:
Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended spectrum beta-lactamases.
Lead Product(s): Pivmecillinam
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Details:
Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases.
Lead Product(s): Pivmecillinam
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
